EpiBiologics is a biotechnology company focused on developing innovative therapies for infectious diseases and immune-related disorders. The company's research and development efforts are centered around leveraging the power of the human immune system to create novel treatments.

EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. Headquartered in San Mateo, EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas. For more information, please visit epibiologics.com and follow us on LinkedIn.

EpiBiologics

Congratulations to EpiBiologics CEO and President, Ann Lee-Karlon, on being named one of the Most Influential Women in Bay Area Business by the San Francisco Business Times.
Ann has deep experience in building pipelines and teams in biotech. We’re excited about her leadership as EpiBiologics advances our new antibody-based protein degradation platform and therapeutics toward the clinic.
#biotech #innovation #SFBTWomen #drugdevelopment


COM:EPIBIOLOGICS

EpiBiologics

Analysis Not Available